Table 4

COX-2 .8473 genotype, NSAIDs use, and risk for breast cancer by hormone receptor status, Long Island Breast Cancer Study Project, 1996–1997

COX-2 .8473 genotype

Aspirin/any NSAID

No use

Ever use

Cases/controls

OR (95% CI)^a

Cases/controls

OR (95% CI)^a

ER or PR positive

TT

Aspirin

191/332

1.0 (ref.)

46/101

0.7 (0.5–1.0)

TC + CC

237/439

1.0 (0.7–1.2)

61/148

0.6 (0.4–0.9)^b

TT

Any NSAID

147/285

1.0 (ref.)

92/155

1.1 (0.8–1.5)

TC + CC

210/371

1.1 (0.9–1.5)

89/223

0.7 (0.5–1.0)^c

ER and PR negative

TT

Aspirin

44/332

1.0 (ref.)

13/101

1.0 (0.5–1.8)

TC + CC

53/439

0.9 (0.6–1.4)

22/148

1.1 (0.6–1.9)^d

TT

Any NSAID

40/285

1.0 (ref.)

18/155

0.8 (0.5–1.5)

TC + CC

39/371

0.8 (0.5–1.2)

37/223

1.2 (0.7–1.9)^e

^aAdjusted for age at reference. ^bMultiplicative interaction term was not significant (P for interaction = 0.78) by Wald statistic. ^cMultiplicative interaction term was significant (P for interaction = 0.02) by Wald statistic. ^dMultiplicative interaction term was not significant (P for interaction = 0.59) by Wald statistic. ^eMultiplicative interaction term was not significant (P for interaction = 0.10) by Wald statistic. CI, confidence interval; ER, estrogen receptor; NSAID, nonsteroidal anti-inflammatory drug; OR, odds ratio; PR, progesteron receptor.

Shen et al. Breast Cancer Research 2006 8:R71   doi:10.1186/bcr1629